Fennec Pharmaceuticals Participating in Healthcare Conference
In a significant announcement, Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a leader in specialty pharmaceutical innovations, has confirmed its participation in an engaging and insightful fireside chat as part of the Piper Sandler 37th Annual Healthcare Conference. This event is set to take place on December 3, 2025, at 1:00 p.m. Eastern Time and will be accessible via webcast.
Details of the Event
As the healthcare community eagerly anticipates this annual conference, Fennec is delighted to share more about the focus areas during this session. This includes their advancements in combating ototoxicity, an unfortunate side effect experienced by cancer patients undergoing cisplatin chemotherapy.
Webcast Information
For those interested in tuning in, the live webcast provides a wonderful opportunity to connect with the latest developments directly from Fennec Pharmaceuticals. Details for the webcast are as follows:
- Date: Wednesday, December 3, 2025
- Time: 1:00 p.m. Eastern Time
Participants can view the live session via the company’s dedicated events page, ensuring that those unable to attend in person can still engage with the discussions.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is on a crucial journey in the pharmaceutical landscape, dedicated to addressing the challenges posed by cisplatin-induced ototoxicity in cancer patients. Their heroic effort is centered around the commercialization of PEDMARK, a treatment specifically designed to reduce this risk, enhancing the quality of life for patients undergoing chemotherapy.
PEDMARK’s notable advances have made headlines with its FDA approval in 2022, followed by subsequent approvals in Europe and the United Kingdom. Brandishing the name PEDMARQSI in European markets, this therapy has become a beacon of hope for many.
The Licensing Agreement
In a bold move to expand its reach, Fennec has entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. This partnership facilitates the commercialization of PEDMARQSI across Europe, the U.K., Australia, and New Zealand. As a result, the product is now available commercially in a select number of countries including the U.K. and Germany, marking a significant milestone in their growth journey.
Intellectual Property and Compliance
Fennec holds Orphan Drug Exclusivity for PEDMARK in the U.S. and has obtained Pediatric Use Marketing Authorization for PEDMARQSI in Europe, ensuring a robust level of market protection which spans a minimum of ten years. Additionally, the company is fortified with patents granting protection until 2039 in both the U.S. and internationally, securing their investment in ongoing research and development.
Staying Connected
Fennec Pharmaceuticals encourages stakeholders and interested parties to stay updated by visiting their official website and following them on social media platforms such as LinkedIn. Keeping abreast of news and updates from Fennec enables investors and patients alike to stay engaged with their journey and advancements in oncology.
Contact Information for Queries
If you have questions about Fennec Pharmaceuticals or seek more detailed insights, please reach out to:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
Frequently Asked Questions
What is Fennec Pharmaceuticals known for?
Fennec Pharmaceuticals is recognized for its innovative treatments aimed at reducing cisplatin-induced ototoxicity in cancer patients.
When is the Piper Sandler Healthcare Conference?
The conference will take place on December 3, 2025, at 1:00 p.m. Eastern Time.
How can I access the webcast?
The live webcast can be accessed through Fennec Pharmaceuticals' events page.
What is PEDMARK?
PEDMARK is Fennec's flagship product designed to minimize the risk of hearing loss in cancer patients undergoing cisplatin-based chemotherapy.
Who can I contact for more information about Fennec?
You can contact Robert Andrade, CFO, or Lindsay Rocco from Elixir Health Public Relations for further inquiries.